Clinical outcome of trabectedin in Japanese patients with soft tissue sarcoma; JMOG multicenter study
Not Applicable
- Conditions
- Malignant soft tissue tumor
- Registration Number
- JPRN-UMIN000034206
- Lead Sponsor
- Japanese Musculoskeletal Oncology Group
- Brief Summary
Initial trabectedin at 1.2 mg/m2 has clinically meaningful benefits for patients with L-sarcoma and certain histological subtypes of TRS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who are not treated in the registered institutions of Japanese Musculoskeletal Oncology Group will be excluded from this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method